AttendMe Owl Logo
AttendMe
Evidence Evolution
Evidence Evolution
Landmark TrialRCTRandomized Controlled Trial

Initiation Strategies for Renal-Replacement Therapy in the Intensive Care Unit

New England Journal of Medicine2016IF: 25.4

Stéphane Gaudry, David Hajage, Frédérique Schortgen, Laurent Martin‐Lefèvre, Bertrand Pons, Éric Boulet, Alexandre Boyer, Guillaume Chevrel, Nicolas Lerolle, Dorothée Carpentier, Nicolas de Prost, Alexandre Lautrette, Anne Bretagnol, Julien Mayaux, Saad Nseir, Bruno Mégarbane, Marina Thirion, Jean-Marie Forel, Julien Maizel, Hodane Yonis, Philippe Markowicz, Guillaume Thiéry, Florence Tubach, Jean‐Damien Ricard, Didier Dreyfuss

PMID: 27181456View on PubMedDOI

Abstract

In a trial involving critically ill patients with severe acute kidney injury, we found no significant difference with regard to mortality between an early and a delayed strategy for the initiation of renal-replacement therapy. A delayed strategy averted the need for renal-replacement therapy in an appreciable number of patients. (Funded by the French Ministry of Health; ClinicalTrials.gov number, NCT01932190.).

Specialty

Nephrology

Featured in Evidence Evolutions